Regeneron Pharmaceuticals, Inc. provided a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference, including preliminary fourth quarter 2023 U.S. net product sales of EYLEA HD of $123 million and EYLEA of $1.34 billion, as well as an acquired in-process research and development charge of $30 million.